567.39 USD
+7.18 (+1.28%)
MEDP gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is growing strongly while it is still valued neutral. This is a good combination! With these ratings, MEDP could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
MEDP had a positive operating cash flow in the past year.
Each year in the past 5 years MEDP has been profitable.
MEDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MEDP's Return On Assets of 24.70% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
MEDP's Return On Equity of 147.46% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 91.45%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 13.99%.
The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
MEDP's Profit Margin of 18.36% is amongst the best of the industry. MEDP outperforms 92.98% of its industry peers.
In the last couple of years the Profit Margin of MEDP has grown nicely.
MEDP has a Operating Margin of 21.50%. This is amongst the best in the industry. MEDP outperforms 89.47% of its industry peers.
In the last couple of years the Operating Margin of MEDP has grown nicely.
MEDP has a Gross Margin of 31.11%. This is in the lower half of the industry: MEDP underperforms 68.42% of its industry peers.
In the last couple of years the Gross Margin of MEDP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
MEDP has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MEDP has less shares outstanding
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 7.94 indicates that MEDP is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.94, MEDP belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.94 |
ROIC/WACC8.79
WACC10.41%
2.3 Liquidity
MEDP has a Current Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP has a Current ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 96.49% of its industry peers.
A Quick Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
MEDP has a Quick ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 94.74% of its industry peers.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.22%, which is quite impressive.
Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
Looking at the last year, MEDP shows a quite strong growth in Revenue. The Revenue has grown by 13.88% in the last year.
MEDP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.62% yearly.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.31% yearly.
Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 12.31% on average per year.
EPS Next Y19.53%
EPS Next 2Y15.31%
EPS Next 3Y13.88%
EPS Next 5Y12.31%
Revenue Next Year19.22%
Revenue Next 2Y15.5%
Revenue Next 3Y13.01%
Revenue Next 5Y12.31%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
MEDP is valuated quite expensively with a Price/Earnings ratio of 39.68.
Compared to the rest of the industry, the Price/Earnings ratio of MEDP is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.26, MEDP is valued quite expensively.
The Price/Forward Earnings ratio is 33.79, which means the current valuation is very expensive for MEDP.
Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than 64.91% of the companies in the same industry.
MEDP is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.68, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.68 | ||
| Fwd PE | 33.79 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDP is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDP indicates a rather cheap valuation: MEDP is cheaper than 80.70% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.62 | ||
| EV/EBITDA | 28.93 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MEDP's earnings are expected to grow with 13.88% in the coming years.
PEG (NY)2.03
PEG (5Y)1.19
EPS Next 2Y15.31%
EPS Next 3Y13.88%
5. Dividend
5.1 Amount
MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:MEDP (12/19/2025, 11:03:00 AM)
567.39
+7.18 (+1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.26%
Inst Owner Change-6.92%
Ins Owners0.37%
Ins Owner Change-6.92%
Market Cap15.98B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target547.08 (-3.58%)
Short Float %6.06%
Short Ratio4.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)5.24%
PT rev (3m)26.25%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)11.36%
EPS NY rev (1m)0.05%
EPS NY rev (3m)5.36%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.68 | ||
| Fwd PE | 33.79 | ||
| P/S | 6.78 | ||
| P/FCF | 23.62 | ||
| P/OCF | 22.47 | ||
| P/B | 54.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.93 |
EPS(TTM)14.3
EY2.52%
EPS(NY)16.79
Fwd EY2.96%
FCF(TTM)24.02
FCFY4.23%
OCF(TTM)25.25
OCFY4.45%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.03
PEG (5Y)1.19
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 7.94 |
F-Score8
WACC10.41%
ROIC/WACC8.79
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.53%
EPS Next 2Y15.31%
EPS Next 3Y13.88%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.22%
Revenue Next 2Y15.5%
Revenue Next 3Y13.01%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.32%
EBIT Next 3Y15.76%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
What is the valuation status of MEDPACE HOLDINGS INC (MEDP) stock?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
How profitable is MEDPACE HOLDINGS INC (MEDP) stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for MEDP stock?
The Earnings per Share (EPS) of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 19.53% in the next year.